LIPLASOME PHARMA ApS: Financial statements 2023
CVR: 29428514
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
LIPLASOME PHARMA ApS (CVR 29428514) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -29,000 and a net result of DKK -20,000 compared with DKK 2,196,000 the year before. Equity in the 2023 report amounted to DKK 2,351,000. The solvency ratio was 99.5%.
- Gross Profit
- DKK -29,000
- Profit/Loss
- DKK -20,000
- Equity
- DKK 2,351,000
- Total Assets
- DKK 2,363,000
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -29 t. | -20 t. | 2.4 mio. | 0 |
| 2022 | - | 2.2 mio. | 2.2 mio. | 2.4 mio. | - |
| 2021 | - | 108 t. | 98 t. | 175 t. | - |
| 2020 | - | -133 t. | -156 t. | 77 t. | - |
| 2019 | - | -81 t. | -33.6 mio. | 233 t. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
LIPLASOME PHARMA ApS has published its annual report for 2022. Gross profit came to DKK 2,202,000, and the net result was DKK 2,196,000.
About LIPLASOME PHARMA ApS
LIPLASOME PHARMA ApS is a Danish company of the type Anpartsselskab based in Vejle, founded in 2006. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named BIO-BEDST ApS. The management consists of Hans-Henrik Horsted Eriksen. The board consists of John Riis Mortensen (chair), Hans-Henrik Horsted Eriksen and Sanjay Kumar Sehgal. The company is owned by BAGGER-SØRENSEN & CO. A/S. The company has 0 employees (2016). In 2025, the company reported a gross profit of DKK -28,000 and a net result of DKK 62,000 compared with DKK -36,000 the year before. Equity in the 2025 report amounted to DKK 2,377,000.